^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Rectal Cancer

    Related cancers:
    1d
    Supportive Oncology Care At Home RCT (clinicaltrials.gov)
    P=N/A, N=300, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    1d
    ETAP: Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer (clinicaltrials.gov)
    P3, N=226, Completed, Institut Paoli-Calmettes | Recruiting --> Completed | Trial completion date: Jan 2024 --> Sep 2025 | Trial primary completion date: Jan 2021 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    2d
    Decoding the association between CT-derived body composition metrics and prognosis in stage II rectal cancer. (PubMed, Insights Imaging)
    Body composition metrics' prognostic utility in stage II rectal cancer is clear. Body composition metrics are associated with clinical outcomes in stage II rectal cancer. Body composition is a predictive biomarker for stage II rectal cancer.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    2d
    Plasma serine and glycine in relation to clinical outcomes following neoadjuvant radiotherapy for rectal cancer. (PubMed, Clin Transl Radiat Oncol)
    This is the first study demonstrating a potential association between the serine/glycine ratio, an indicator of SHMT enzyme activity, and rectal cancer recurrence. Further studies are warranted to confirm these findings, as well as investigate underlying biological mechanisms and potentially explore strategies to target SHMT enzyme activity in the context of cancer treatment.
    Clinical data • Journal
    |
    SHMT1 (Serine Hydroxymethyltransferase 1)
    2d
    CONTICARE: "Impact of Pelvic Floor Prehabilitation Using Biofeedback on the Severity of the Low Anterior Resection Syndrome in Patients Undergoing a Total Mesorectal Excision for Rectal Cancer" (clinicaltrials.gov)
    P=N/A, N=120, Terminated, Nantes University Hospital | N=174 --> 120 | Trial completion date: May 2022 --> Dec 2025 | Unknown status --> Terminated | Trial primary completion date: Oct 2021 --> Dec 2025; lack of inclusion
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    3d
    Interfacial electronic modulation of ultrasmall heterojunction nanozymes for rectal cancer biomarkers analysis. (PubMed, Biosens Bioelectron)
    It also facilitates visual tumor-normal tissue differentiation based on its superior catalytic performance. This work provides a paradigm for activity-oriented nanozyme design via interfacial electronic modulation.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    5d
    Rectal Gastrointestinal Stromal Tumor Complicated by Tumor Lysis Syndrome after Imatinib Initiation: A Rare and Fatal Case. (PubMed, Case Rep Gastroenterol)
    Surgical resection is the standard treatment for localized GIST. Imatinib is the first-line prescribed treatment, with particular attention to potentially life-threatening adverse effects.
    Journal
    |
    ANO1 (Anoctamin 1)
    |
    imatinib
    5d
    Biomarker-Guided Inflammatory Control and Multidimensional Recovery After Abdominoperineal Resection: A Prospective Cohort Study. (PubMed, Asia Pac J Clin Oncol)
    A perioperative, biomarker-guided integrative program targeting inflammatory and immunometabolic vulnerability was associated with improved psychosocial and functional recovery after APR, with favorable effects on immune restoration and exploratory survival outcomes, and with excellent safety and adherence. Longer follow-up will be required to determine whether the observed immune and survival benefits remain durable over time.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • CRP (C-reactive protein)
    5d
    Robotic-Assisted Compared to Laparoscopic Resection of Rectal Cancer in Patients Aged ≥65 Years: A Propensity Score-Matched Analysis of the NCDB. (PubMed, J Laparoendosc Adv Surg Tech A)
    In older adults with rectal cancer, robotic surgery was associated with significant reduction in conversion rates and potentially modestly improved lymph node harvest, while both approaches provided comparable safety and long-term oncologic outcomes.These findings must be considered in the context of the heterogenous definitions of conversion and the availability of the robotic platform and training in both robotic and laparoscopic technqiues.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    5d
    Diagnostic Accuracy and Prognostic Value of 18F FDG PET-CT in the Follow up of Patients With Colorectal Carcinoma. (clinicaltrials.gov)
    P=N/A, N=46, Not yet recruiting, Assiut University
    New trial
    5d
    Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment (clinicaltrials.gov)
    P2, N=38, Recruiting, Emory University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • RAS mutation • RAS wild-type • HER-2 positive + RAS wild-type
    |
    Ziihera (zanidatamab-hrii)
    8d
    A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer (clinicaltrials.gov)
    P2, N=44, Recruiting, Chinese PLA General Hospital
    New P2 trial • pMMR
    |
    AiRuiKa (camrelizumab) • capecitabine • oxaliplatin